Recent studies also identified associations between high TMB and clinical benefit in NSCLC, melanoma, and bladder cancer patients when treated with PD-1/PD-L1 inhibitors or CTLA4 blockade [1, 44]. This evidence concerns the gene CTLA4 and urinary bladder cancer.